LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace…
Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 MinuteNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) --…
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated…
-- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from…
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy…
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused…
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the…
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered…
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ETBEDMINSTER, N.J., Jan. 23, 2023 (GLOBE…
– State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local…